Ruixiang Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ruixiang Zhang has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Yin Li
Section of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
17 shared publications - Guojie Feng
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
16 shared publications - Jianjun Qin
Section of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
16 shared publications - Jiao Li
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
16 shared publications - Jiaqi Xu
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
16 shared publications - Liyan Xue
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
16 shared publications
Latest Publications
- Open Access
- 22 April 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (4) , e014562
Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma
Background: Neoadjuvant immune checkpoint blockade (ICB) combined with chemotherapy has demonstrated higher response rates than chemotherapy alone in resectable esophageal squamous cell carcinoma (ESCC). Although tumor microenvironment (TME) features associated with treatment response have been studied in the contexts of both chemotherapy and immunotherapy, direct comparisons of these characteristics and their implications for novel therapeutic development remain largely unexplored. Methods: Paired pretreatment and post-treatment tumor samples were prospectively collected from 55 patients with locally advanced ESCC enrolled in a multicenter, phase 3 clinical trial (ChiCTR2000040034). Patients were randomized to receive neoadjuvant chemotherapy (paclitaxel with cisplatin, TP; n=14) or its combination with PD-1 blockade (camrelizumab, albumin-bound paclitaxel and cisplatin/paclitaxel and cisplatin, Cam+nab-TP/TP; n=41), followed by surgical resection. Pathological response was defined based on Mandard’s Tumor Regression Grade scoring system. Changes in immune cell populations and tumor-associated antigens (TAAs) within the TME in relation to response were characterized using single-cell RNA and T cell receptor sequencing. Results: Both chemotherapy and chemoimmunotherapy responders exhibited shared temporal dynamics including dendritic cell remodeling, cytotoxic CD8 + T cell contraction, and memory T cell expansion, with chemoimmunotherapy uniquely suppressing the clonal expansion of GZMB + TIGIT + T cells. In contrast, non-responders failed to elicit effective antitumor immunity and displayed persistent expression of targetable TAAs, fully preserved HLA machinery, and clonal expansion of dysfunctional GZMB + TIGIT + T cells. Conclusions: Our study identifies key immune contributors correlated with response to neoadjuvant therapies and a panel of TAAs in non-responders. These findings support the development of TAA-targeted therapeutic vaccines and combination strategies incorporating ICB to overcome resistance in non-responders.
- 22 April 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (4) , e014562
Open AccessSingle-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma
Background: Neoadjuvant immune checkpoint blockade (ICB) combined with chemotherapy has demonstrated higher response rates than chemotherapy alone in resectable esophageal squamous cell carcinoma (ESCC). Although tumor microenvironment (TME) features associated with treatment response have been studied in the contexts of both chemotherapy and immunotherapy, direct comparisons of these characteristics and their implications for novel therapeutic development remain largely unexplored. Methods: Paired pretreatment and post-treatment tumor samples were prospectively collected from 55 patients with locally advanced ESCC enrolled in a multicenter, phase 3 clinical trial (ChiCTR2000040034). Patients were randomized to receive neoadjuvant chemotherapy (paclitaxel with cisplatin, TP; n=14) or its combination with PD-1 blockade (camrelizumab, albumin-bound paclitaxel and cisplatin/paclitaxel and cisplatin, Cam+nab-TP/TP; n=41), followed by surgical resection. Pathological response was defined based on Mandard’s Tumor Regression Grade scoring system. Changes in immune cell populations and tumor-associated antigens (TAAs) within the TME in relation to response were characterized using single-cell RNA and T cell receptor sequencing. Results: Both chemotherapy and chemoimmunotherapy responders exhibited shared temporal dynamics including dendritic cell remodeling, cytotoxic CD8 + T cell contraction, and memory T cell expansion, with chemoimmunotherapy uniquely suppressing the clonal expansion of GZMB + TIGIT + T cells. In contrast, non-responders failed to elicit effective antitumor immunity and displayed persistent expression of targetable TAAs, fully preserved HLA machinery, and clonal expansion of dysfunctional GZMB + TIGIT + T cells. Conclusions: Our study identifies key immune contributors correlated with response to neoadjuvant therapies and a panel of TAAs in non-responders. These findings support the development of TAA-targeted therapeutic vaccines and combination strategies incorporating ICB to overcome resistance in non-responders.
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Figure 5. Results of univariate analyses for overall survival
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Figure 5. Results of univariate analyses for overall survival
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Data from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Purpose:This phase II trial investigated the safety and efficacy of chemoradiotherapy (CRT) followed by immunochemotherapy (iCT) and surgery in unresectable locally advanced esophageal squamous cell carcinoma (ESCC).Patients and Methods:Patients with unresectable locally advanced ESCC received radiotherapy (50 Gy/25f, 5 days/week) and nab-paclitaxel (100 mg on day 1/week) plus cisplatin (25 mg/m2 on day 1/week) for 5 weeks, followed by tislelizumab (200 mg on day 1/cycle) plus chemotherapy (nab-paclitaxel 150 mg/m2 and cisplatin 75 mg/m2 on day 2/cycle) for two 21-day cycles. Patients who converted to resectable underwent surgery 2 to 4 weeks afterward. The primary endpoint was a 1-year progression-free survival (PFS) rate.Results:Thirty patients were enrolled and underwent CRT (median follow-up: 21 months), of whom 24 received iCT. Twenty (66.7%) patients achieved resectability (R0: 95.2%; pathologic complete response: 65.0%; major pathologic response: 90.0%). One-year PFS and overall survival (OS) rates were 79.4% and 89.6%, respectively. The R0 resection group exhibited longer PFS (median, not reached vs. 8.4 months; HR = 0.28; 95% confidence interval, 0.08–0.84; P = 0.02) and OS (median, not reached vs. 19.2 months; HR = 0.18; 95% confidence interval, 0.04–0.73; P < 0.01) than the nonsurgery group. Grade 3 to 4 adverse events were observed in 11 (11/30, 36.7%) patients, and immune-related pneumonitis was observed in 5 (5/24, 20.8%) patients. Post-CRT minimal residual disease before surgery was associated with unfavorable PFS and OS.Conclusions:Our study met the primary endpoint. Conversion CRT and subsequent iCT followed by surgery was a promising treatment strategy for unresectable locally advanced ESCC.
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Purpose:This phase II trial investigated the safety and efficacy of chemoradiotherapy (CRT) followed by immunochemotherapy (iCT) and surgery in unresectable locally advanced esophageal squamous cell carcinoma (ESCC).Patients and Methods:Patients with unresectable locally advanced ESCC received radiotherapy (50 Gy/25f, 5 days/week) and nab-paclitaxel (100 mg on day 1/week) plus cisplatin (25 mg/m2 on day 1/week) for 5 weeks, followed by tislelizumab (200 mg on day 1/cycle) plus chemotherapy (nab-paclitaxel 150 mg/m2 and cisplatin 75 mg/m2 on day 2/cycle) for two 21-day cycles. Patients who converted to resectable underwent surgery 2 to 4 weeks afterward. The primary endpoint was a 1-year progression-free survival (PFS) rate.Results:Thirty patients were enrolled and underwent CRT (median follow-up: 21 months), of whom 24 received iCT. Twenty (66.7%) patients achieved resectability (R0: 95.2%; pathologic complete response: 65.0%; major pathologic response: 90.0%). One-year PFS and overall survival (OS) rates were 79.4% and 89.6%, respectively. The R0 resection group exhibited longer PFS (median, not reached vs. 8.4 months; HR = 0.28; 95% confidence interval, 0.08–0.84; P = 0.02) and OS (median, not reached vs. 19.2 months; HR = 0.18; 95% confidence interval, 0.04–0.73; P < 0.01) than the nonsurgery group. Grade 3 to 4 adverse events were observed in 11 (11/30, 36.7%) patients, and immune-related pneumonitis was observed in 5 (5/24, 20.8%) patients. Post-CRT minimal residual disease before surgery was associated with unfavorable PFS and OS.Conclusions:Our study met the primary endpoint. Conversion CRT and subsequent iCT followed by surgery was a promising treatment strategy for unresectable locally advanced ESCC.
- 15 November 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (22) , 5061-5072
Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Purpose: This phase II trial investigated the safety and efficacy of chemoradiotherapy (CRT) followed by immunochemotherapy (iCT) and surgery in unresectable locally advanced esophageal squamous cell carcinoma (ESCC). Patients and Methods: Patients with unresectable locally advanced ESCC received radiotherapy (50 Gy/25f, 5 days/week) and nab-paclitaxel (100 mg on day 1/week) plus cisplatin (25 mg/m2 on day 1/week) for 5 weeks, followed by tislelizumab (200 mg on day 1/cycle) plus chemotherapy (nab-paclitaxel 150 mg/m2 and cisplatin 75 mg/m2 on day 2/cycle) for two 21-day cycles. Patients who converted to resectable underwent surgery 2 to 4 weeks afterward. The primary endpoint was a 1-year progression-free survival (PFS) rate. Results: Thirty patients were enrolled and underwent CRT (median follow-up: 21 months), of whom 24 received iCT. Twenty (66.7%) patients achieved resectability (R0: 95.2%; pathologic complete response: 65.0%; major pathologic response: 90.0%). One-year PFS and overall survival (OS) rates were 79.4% and 89.6%, respectively. The R0 resection group exhibited longer PFS (median, not reached vs. 8.4 months; HR = 0.28; 95% confidence interval, 0.08–0.84; P = 0.02) and OS (median, not reached vs. 19.2 months; HR = 0.18; 95% confidence interval, 0.04–0.73; P < 0.01) than the nonsurgery group. Grade 3 to 4 adverse events were observed in 11 (11/30, 36.7%) patients, and immune-related pneumonitis was observed in 5 (5/24, 20.8%) patients. Post-CRT minimal residual disease before surgery was associated with unfavorable PFS and OS. Conclusions: Our study met the primary endpoint. Conversion CRT and subsequent iCT followed by surgery was a promising treatment strategy for unresectable locally advanced ESCC.
- 15 November 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (22) , 5061-5072
Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Purpose: This phase II trial investigated the safety and efficacy of chemoradiotherapy (CRT) followed by immunochemotherapy (iCT) and surgery in unresectable locally advanced esophageal squamous cell carcinoma (ESCC). Patients and Methods: Patients with unresectable locally advanced ESCC received radiotherapy (50 Gy/25f, 5 days/week) and nab-paclitaxel (100 mg on day 1/week) plus cisplatin (25 mg/m2 on day 1/week) for 5 weeks, followed by tislelizumab (200 mg on day 1/cycle) plus chemotherapy (nab-paclitaxel 150 mg/m2 and cisplatin 75 mg/m2 on day 2/cycle) for two 21-day cycles. Patients who converted to resectable underwent surgery 2 to 4 weeks afterward. The primary endpoint was a 1-year progression-free survival (PFS) rate. Results: Thirty patients were enrolled and underwent CRT (median follow-up: 21 months), of whom 24 received iCT. Twenty (66.7%) patients achieved resectability (R0: 95.2%; pathologic complete response: 65.0%; major pathologic response: 90.0%). One-year PFS and overall survival (OS) rates were 79.4% and 89.6%, respectively. The R0 resection group exhibited longer PFS (median, not reached vs. 8.4 months; HR = 0.28; 95% confidence interval, 0.08–0.84; P = 0.02) and OS (median, not reached vs. 19.2 months; HR = 0.18; 95% confidence interval, 0.04–0.73; P < 0.01) than the nonsurgery group. Grade 3 to 4 adverse events were observed in 11 (11/30, 36.7%) patients, and immune-related pneumonitis was observed in 5 (5/24, 20.8%) patients. Post-CRT minimal residual disease before surgery was associated with unfavorable PFS and OS. Conclusions: Our study met the primary endpoint. Conversion CRT and subsequent iCT followed by surgery was a promising treatment strategy for unresectable locally advanced ESCC.
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Figure 1. Kaplan-Meier estimates of survival in the R0 resection and non-surgery group
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Figure 1. Kaplan-Meier estimates of survival in the R0 resection and non-surgery group
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Figure 3. Prognostic analysis of esophageal squamous cell carcinoma in MRD status
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Figure 3. Prognostic analysis of esophageal squamous cell carcinoma in MRD status
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Table 8. Associations of genetic alterations with prognosis.
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Table 8. Associations of genetic alterations with prognosis.
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Figure 4. Results of univariate analyses for progression-free survival
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Figure 4. Results of univariate analyses for progression-free survival
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Table 7. Associations of postoperative pathological characteristics with t1 and t2 MRD status
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Table 7. Associations of postoperative pathological characteristics with t1 and t2 MRD status
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Figure 2. The association between PD-L1 expression and survival in patients who received R0 resection (PD-L1 CPS <10 vs. PD-L1 CPS ≥10)
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
Supplementary Figure 2. The association between PD-L1 expression and survival in patients who received R0 resection (PD-L1 CPS <10 vs. PD-L1 CPS ≥10)